Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks the peripheral nerves. The syndrome can lead to weakness, numbness, and, in severe cases, paralysis. There are no specific pharmaceutical companies dedicated solely to GBS, but various companies may be involved in researching treatments or therapies for neurological disorders.
Latest Guillain-Barre Syndrome Companies Update
March 2022: OpdualagTM (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a single intravenous infusion, has been approved by the United States Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.1 The approval is based on the RELATIVITY-047 Phase 2/3 study. The trial's primary goal, progression-free survival (PFS), was met, and Opdualag more than doubled the median PFS when compared to nivolumab alone. The following clinically significant immune-mediated adverse events occurred at a rate of 1% (unless otherwise specified) in patients who received OPDIVO monotherapy or OPDIVO in combination with YERVOY, or were reported in patients who received other PD-1/PD-L1 blocking antibodies. Some adverse responses, such as Guillain-Barré syndrome, have resulted in severe or fatal instances.
Guillain-Barre Syndrome Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)